
1/8 🚀 AtheroPortal is now live! A centralized platform for exploring atherosclerotic plaque and clinical data, transcriptomics, and advanced analyses from the Athero-Express Biobank Study. 👉 atheroportal.nl

Athero-Express & AAA-Express™ Biobank Studies @UMCUtrecht: biomarkers | atherosclerosis | aneurysms | genomics | epidemiology

1/8 🚀 AtheroPortal is now live! A centralized platform for exploring atherosclerotic plaque and clinical data, transcriptomics, and advanced analyses from the Athero-Express Biobank Study. 👉 atheroportal.nl

Some concrete examples here: 👉 modern cardiovascular drug development has been largely shaped by targets, where variation in their genes has been linked to disease risk (PCSK9, APOC3, ANGPTL3, FXI, LPA, IL6 etc.) 👉 specifically, human genetic evidence has been translated to approved drugs for hypercholesterolemia (PCSK9, approved), boosted the clinical development of new categories of drugs (e.g. LPA, IL6, in phase 3), or informed new translational pathways and indications for others (e.g. FXI, awaiting approval for non-cardioembolic ischemic stroke) 👉 GWAS hits in Alzheimer's disease (e.g. TREM2, CLU, BIN1) have pointed to neuroinflammation and microglial biology, influencing drug development, even if clinical translation is still ongoing (TREM2) 👉 similar story for ALS, where beyond pointing to Mendelian cases, for which targeted therapies are being developed, drugs emerging from GWAS hits are about to start being tested in clinical trials (UNC13A) 👉 many similar examples from autoimmune diseases, e.g. IL23/IL23R approved for psoriasis and inflammatory bowel disease, TYK2 inhibition approved for psoriasis now expanding to other indications, PTPN22/LYP emerging as a promising target in clinical development 👉 first approved drugs for dry age-related macular degeneration (C3 and C5 inhibitors) targeting the complement, were largely influenced by discovery of hits in several complement genes in GWAS 👉 the whole booming field of RNA therapeutics (especially liver-targeting) depends on sequencing the targets and so is directly linked to the human genome project
This is a common critique of the genomic revolution. Indeed, beyond rare diseases and oncology, germline genetics has underdelivered on early promises around predicting disease risk, clinical outcomes, or drug response. With few noteworthy exceptions, for most complex traits, predictive performance remains modest. But human genetic studies have offered unique insights into disease biology and pointed to concrete therapeutic opportunities, some of which have already translated into clinical benefit. These contributions are often overlooked because the field was initially framed around personalized medicine.

By fine-mapping GWAS signals across disease endpoints, biomarkers, and molecular traits (eQTLs/pQTLs), and then colocalizing across credible sets, the study offers the most systematic exploration of genetic pleiotropy to date.

This new preprint by Open Targets is one of the most comprehensive efforts to date to connect the dots across all available (>100K) GWAS datasets that have been generated over the last two decades👇

Tim Peters wrote a ✨ great blogpost ✨in laymen's terms on our paper. Check it out here 👉🏽 vanderlaanscience.nl/news/ph…


🚀 Thrilled to announce our latest #preprint on intraplaque haemorrhage (IPH) quantification and molecular 🧬characterisation of carotid plaques using deep learning. A thread 🧵👇🏽

Great work by Tim Peters and Senna Krebbers. From our broader team @CircHealth_umcu @UMCU_Intl @gpasterkamp @InnovatieHester

8/8 Supported in part by the EU Pathfinder MIRACLE and HealthHolland 'Getting the Perfect Image' projects. 🔗 uefconnect.uef.fi/en/miracle Explore the portal: 👉 atheroportal.nl #Atherosclerosis #OpenScience #FAIR #CardiovascularResearch

7/8 This democratizes plaque data in a user-friendly way — enabling researchers who lack the skills to analyze different data modalities to pursue their interests. Transparency, reproducibility, collaboration. In line with the #FAIR principles of #OpenScience.

6/8 Who can access: 🔬 Academic researchers — register, share background & purpose, get approved. 🏢 Industry — access only after a public-private partnership agreement with our partner AtheroScreen, case-by-case: 🔗 atheroscreen.nl

5/8 ⚠️ Important: AtheroPortal exposes only aggregate, summary-level results. No individual-level (per-patient) data are accessible through the portal at any time. For individual-level data or samples, apply through Athero-Express' formal procedure at: 🔗 doi.org/10.34894/4IKE3T

4/8 What AtheroPortal does: 🧬 Enter a gene or target of interest → retrieve the full range of aggregate associations across the cohort: expression patterns, genotype-phenotype associations, links to plaque morphology. The human-tissue context for your cell/mouse findings.

3/8 Athero-Express is one of the largest biobanks of human plaques worldwide, with extensive clinical and phenotypic data. Each plaque is linked to patient information, histology, and increasingly to genomic, transcriptomic, and proteomic readouts. 🔗 atheroexpress.nl

2/8 Why human plaques matter: #Atherosclerosis is often asymptomatic but can present acutely as a heart attack or stroke. The effects of genes identified in mouse models are rarely confirmed at scale through human genetic studies — so researchers seek validation in human lesions.

Great collaboration as detailed in the thread and another first author paper for @francescocist9 from my group! 😊
🚀 Thrilled to announce our latest #preprint on intraplaque haemorrhage (IPH) quantification and molecular 🧬characterisation of carotid plaques using deep learning. A thread 🧵👇🏽